Bayer's Nexavar flunks a new test in liver cancer study; Vital Therapies regroups around new IPO;

@FierceBiotech: Kythera buys back Bayer's stake in PhIII chin-fat therapy in $84M deal. News | Follow @FierceBiotech

@JohnCFierce: Commentary--The dying child vs. the biotech: Everybody loses. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Yesteryear's megamergers are, in part, driving Big Pharma's external R&D push, says John LaMattina. Forbes piece | Follow @DamianFierce

@EmilyMFierce: Scientists from Notre Dame ID new class of antibiotics to combat MRSA. Story | Follow @EmilyMFierce

> Bayer and Onyx Pharmaceuticals' ($ONXX) Nexavar has seen a lot of success as a liver-cancer treatment, topping market threats from the likes of Bristol-Myers Squibb and Pfizer in head-to-head trials on its way to blockbuster status. But as an adjuvant therapy for liver cancer? It could be awhile--if ever. Tuesday, the drug missed its target in a Phase III trial, failing to meet the study's main goal of improving recurrence-free survival. Story

> Vital Therapies is taking a fresh stab at an IPO. The biotech pulled back from its last attempt to come up with about $75 million. The new S-1 does not include specific terms. Story

> Japan's RIKEN research institute is considering retracting two high profile stem cell studies published in January, with the lead scientist saying he was no longer sure about the data. Report

Medical Device News

@FierceMedDev: Lombard Medical in the U.K. detailed plans for a proposed $80M IPO driven by its aortic repair device. S-1 form | Follow @FierceMedDev

@MarkHFierce: Exosome Diagnostics raised $27M to bring its prostate cancer urine test to market. More | Follow @MarkHFierce

@MichaelGFierce: Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Industry report shows bleak 2013 for med tech industry. Story | Follow @EmilyWFierce

@GalenMoore: Spanish researchers find a protein adults need for brain plasticity could delay the effects of Alzheimer's disease. Abstract | Follow @GalenMoore

> Roche and Bayer expand their companion Dx partnership into multiple projects. Article

> TriVascular envisions a $100M IPO to propel AAA stent graft rollout. News

Pharma News

@FiercePharma: Yesterday's top-read news: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma

@TracyStaton: Every Dog Has Its Data: The quantified self for pets, via The New York Times. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: Pfizer's Effexor XR one of a host of recalls lately that include products from Mylan, Baxter and Gilead. More | Follow @EricPFierce

@CarlyHFierce: As promised: BTG recoils at rattlesnake roundup 'gassing.' Item | Follow @CarlyHFierce

> Bayer's Nexavar falls short in new liver cancer trial. Story

> Pharma wins battle against proposed Medicare reimbursement changes. More

Biotech Research News

> University of Notre Dame team IDs new class of antibiotics. Article

> Stem cell therapy improves Parkinson's symptoms in monkeys. Story

> NIH faces flat funds in president's 2015 budget proposal. News

> Seattle BioMed receives $10M NIAID grant to lead AIDS vaccine effort. News

> Antipsychotic drugs may have another use: Treating deadly brain tumors. Story

> OHSU opens new stem cell research center. Brief

Pharma Manufacturing News

> BMS joins Merck with plans to whack plants in Ireland. News

> Global rise in pain drug use puts the hurt on Tasmania's poppy production. Story

> Source: Ranbaxy shops for Nexium API to salvage lucrative launch. Article

> Ranbaxy recalls generic Lipitor after druggist finds 20-mg dose in 10-mg bottle. News

> Pfizer recalls bottles of antidepressant that might have a heart drug mixed in. Story

> Pfizer is expanding its plant in Indonesia--again. Brief

 

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.